BTIG Research Forecasts Strong Price Appreciation for Tempus AI (NASDAQ:TEM) Stock

Tempus AI (NASDAQ:TEM) had its target price hoisted by equities researchers at BTIG Research from $70.00 to $80.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price objective would suggest a potential upside of 30.61% from the company’s current price.

Other research analysts also recently issued reports about the stock. Stifel Nicolaus decreased their target price on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research note on Monday, August 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a report on Friday, July 31st. TD Cowen reiterated a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Guggenheim upped their price objective on shares of Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Finally, Wolfe Research began coverage on Tempus AI in a research note on Tuesday, June 2nd. They set a “peer perform” rating for the company. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $65.69.

Tempus AI Stock Up 24.1%

NASDAQ TEM opened at $61.25 on Thursday. The stock has a market cap of $11.05 billion, a PE ratio of -42.53 and a beta of 3.58. Tempus AI has a fifty-two week low of $40.77 and a fifty-two week high of $104.32. The business has a 50 day moving average price of $52.10 and a two-hundred day moving average price of $51.16. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. Tempus AI’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.22) earnings per share. As a group, sell-side analysts predict that Tempus AI will post -1.38 EPS for the current fiscal year.

Insider Activity at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 250,000 shares of the business’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $42.06, for a total value of $10,515,000.00. Following the completion of the sale, the chief executive officer owned 200,000 shares of the company’s stock, valued at approximately $8,412,000. The trade was a 55.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James William Rogers sold 11,529 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $634,095.00. Following the completion of the sale, the chief financial officer owned 114,866 shares in the company, valued at approximately $6,317,630. This trade represents a 9.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 684,424 shares of company stock valued at $33,255,565. Insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently bought and sold shares of the company. Pictet Asset Management Holding SA grew its position in shares of Tempus AI by 291.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock worth $2,948,000 after acquiring an additional 36,096 shares in the last quarter. Bogart Wealth LLC raised its position in shares of Tempus AI by 365,087.5% during the 4th quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock valued at $3,450,000 after acquiring an additional 58,414 shares in the last quarter. Eagle Health Investments LP acquired a new stake in shares of Tempus AI during the 1st quarter valued at approximately $11,588,000. Alethea Capital Management LLC bought a new position in Tempus AI during the fourth quarter worth $1,863,000. Finally, Hussman Strategic Advisors Inc. lifted its stake in Tempus AI by 100.0% during the fourth quarter. Hussman Strategic Advisors Inc. now owns 42,000 shares of the company’s stock worth $2,480,000 after purchasing an additional 21,000 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.